Insider Selling: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Insider Sells 3,129 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Ellen Chiniara sold 3,129 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $41.75, for a total transaction of $130,635.75. Following the sale, the insider now directly owns 54,826 shares of the company’s stock, valued at $2,288,985.50. This represents a 5.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Kymera Therapeutics Price Performance

Shares of Kymera Therapeutics stock opened at $40.92 on Wednesday. The stock’s 50-day moving average is $44.34 and its 200 day moving average is $43.94. Kymera Therapeutics, Inc. has a one year low of $25.02 and a one year high of $53.27. The firm has a market cap of $2.65 billion, a price-to-earnings ratio of -17.49 and a beta of 2.19.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.01. The company had revenue of $3.74 million during the quarter, compared to analyst estimates of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Kymera Therapeutics’s revenue for the quarter was down 20.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.90) EPS. On average, sell-side analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp boosted its holdings in Kymera Therapeutics by 19.3% in the second quarter. Bank of New York Mellon Corp now owns 156,211 shares of the company’s stock worth $4,663,000 after acquiring an additional 25,317 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Kymera Therapeutics by 12.4% in the 2nd quarter. Rhumbline Advisers now owns 64,535 shares of the company’s stock worth $1,926,000 after purchasing an additional 7,143 shares in the last quarter. Arizona State Retirement System grew its position in Kymera Therapeutics by 15.6% in the 2nd quarter. Arizona State Retirement System now owns 12,830 shares of the company’s stock valued at $383,000 after purchasing an additional 1,730 shares during the period. Quest Partners LLC increased its stake in Kymera Therapeutics by 1,402.0% during the 2nd quarter. Quest Partners LLC now owns 5,212 shares of the company’s stock valued at $156,000 after purchasing an additional 4,865 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its holdings in Kymera Therapeutics by 2.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 405,870 shares of the company’s stock worth $12,115,000 after buying an additional 10,731 shares during the last quarter.

Analyst Ratings Changes

A number of analysts have recently weighed in on KYMR shares. Leerink Partners reaffirmed an “outperform” rating and set a $60.00 price target on shares of Kymera Therapeutics in a report on Friday, December 27th. Truist Financial reaffirmed a “buy” rating and issued a $53.00 target price (down previously from $54.00) on shares of Kymera Therapeutics in a report on Friday, November 1st. Oppenheimer boosted their target price on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Friday, September 27th. BMO Capital Markets initiated coverage on Kymera Therapeutics in a research note on Friday, December 6th. They issued a “market perform” rating and a $55.00 price target for the company. Finally, Stephens initiated coverage on Kymera Therapeutics in a report on Monday, November 18th. They issued an “overweight” rating and a $65.00 target price for the company. Three analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Kymera Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $55.38.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.